Chemomab Therapeutics is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need
Our Vision
Innovation
Translating novel biological insights into transformational treatments
Evidence Driven
Drug discovery and development that are built on a deep understanding of central fibrotic and inflammatory mediators and pathways
Improving Lives
Committed to improving the quality of life of patients suffering from seriously debilitating and life-threatening diseases
Innovation & Discovery
Chemomab discovered the key role of the soluble protein CCL24 as a driver of the fibro-inflammatory vicious cycle that promotes liver, skin and lung fibrosis
The Challenge
Fibrosis-related diseases are common and represent a significant unmet need that can dramatically affect patients’ health and quality of life
Damaged tissue typically repairs itself through a sequence of controlled inflammatory and fibrotic processes. However, uncontrolled healing processes can create a vicious cycle of inflammation and fibrosis – an excessive, sustained, chronic inflammatory response that activates fibroblasts and replaces functional tissue with fibrous scar tissue.
CCL24 – a Key Player
Regulating CCL24 is key to halting fibrosis-related conditions
Chemomab discovered that the soluble protein CCL24 plays a key role in promoting inflammation and fibrosis via a dual pathway. CCL24 promotes the recruitment of immune cells to the damaged tissue and supports immune cell polarization, which can create a pro-fibrotic environment. In parallel, CCL24 promotes fibrogenesis by directly activating tissue fibroblasts, enhancing their transition into myofibroblasts and inducing the uncontrolled production of extracellular matrix.
Nebokitug Therapeutic Platform
Pioneering innovation to treat fibrosis-related diseases.
Nebokitug (CM-101) is designed to bind to and neutralize CCL24, thereby interfering with the main pathologies that promote fibrosis and inflammation. It is highly effective in ameliorating fibrosis, as shown across multiple preclinical studies, including models of liver, skin and lung fibrosis. Chemomab reported positive data from 5 nebokitug clinical trials, including 15-week and 48-week data from the Phase 2 SPRING trial in primary sclerosing cholangitis, a devastating fibrotic disease of the bile ducts. Treatment with nebokitug also improved disease-related biomarkers in a liver fibrosis trial and in a study in acute lung injury.
To learn more about how nebokitug interrupts the fibro-inflammatory cycle, see our Mechanism of Action video at MOA video.
Product Pipeline
